Evidence map›Paper›PMID 36175333›Full record

ArticleInfection, disease & health2023

Considering the precautionary principle and its application to MRSA and SARS-CoV-2 as emerging novel pathogens of their time.

Joanna Harris, Hazel Maxwell, Susan Dodds

Open access · greenAbstract read
In one paragraph

Article in Infection, disease & health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Joanna HarrisDirector of Infection Prevention and Control, Infection Management and Control Service (IMACS), Illawarra Shoalhaven Local Health District (ISLHD), Level 1 Lawson House, Wollongong Hospital, Loftus St, Wollongong 2500, NSW, Australia. Electronic address: Joanna.harris@health.nsw.gov.au.
Hazel MaxwellSenior Lecturer Health Sciences, University of Tasmania, Sydney, Australia.
Susan DoddsDeputy Vice-Chancellor, Research and Industry Engagement, La Trobe University, Melbourne, Victoria, Australia; School of Humanities and Languages, UNSW (Australia); School of Humanities, University of Tasmania, Australia.
University of Tasmania · AUWollongong Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the 1980s Contact Precautions were introduced as a precautionary measure to control the emerging threat of antimicrobial resistance in hospitals, particularly methicillin resistant Staphylococcus aureus (MRSA). Today, antimicrobial resistance remains a concerning global public health threat, and a focus for hospital patient safety priorities. In late 2019 a novel respiratory virus described as SARS-CoV-2, was reported. Just as MRSA had prompted control measures developed in the context of limited information and understanding of the pathogen, public health control measures against SARS-CoV-2 were promptly and strictly implemented. Whilst SARS-CoV-2 control measures were successful at containing the virus, numerous detrimental socio-economic and health impacts have led to a rebalancing of harms versus benefits and loosening of restrictions. Conversely, evidence collated over the past 50 years, suggests that Contact Precautions are not superior to well-applied standard infection prevention and control precautions in controlling MRSA acquisition in hospitals. Several harms associated with Contact Precautions, affecting patient safety, financial costs, and organisational culture, are described. However, rebalancing of hospital MRSA control policies has been slow to materialise. This commentary invites infection prevention and control policy makers to reflect and revise policies for the control of MRSA in hospitals so that harms do not outweigh benefits.

Indexed as

Anti-Infective AgentsCOVID-19Methicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsAdministrative PersonnelHumansSARS-CoV-2SulfadiazineAnti-Infective AgentsSulfadiazineContact precautionsEmerging novel pathogensEthical practiceMRSAPrecautionary principleSARS CoV-2

Identifiers

PMID36175333
PMCPMC9458704
OpenAlexW4295021419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.